[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629805":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":27,"locations":33,"responsibleParty":49,"collaborators":24,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":24,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":24,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":24,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Xuanwu Hospital, Beijing","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oliceridine","EXPERIMENTAL","Loading dose of 1.5 mg IV at dural closure. PCIA pump: Oliceridine 0.4 mg\u002Fkg diluted to 100 ml with normal saline. Settings: background infusion 1 ml\u002Fh, bolus dose 0.5 ml, lockout time 6 min, maximum 27 mg\u002F24h. Duration: 48h.",[13],"Drug: Oliceridine",{"label":15,"type":16,"description":17,"interventionNames":18},"Sufentanil","ACTIVE_COMPARATOR","Loading dose of 7.5 mcg IV at dural closure. PCIA pump: Sufentanil 2 mcg\u002Fkg diluted to 100 ml with normal saline. Settings: background infusion 1 ml\u002Fh, bolus dose 0.5 ml, lockout time 6 min. Duration: 48h.",[19],"Drug: Sufentanil",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},"Wei Xiao, Dr.","CONTACT","+86-13810971299","kitten15@126.com",[34],{"facility":35,"status":36,"city":37,"state":24,"zip":24,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Xuanwu Hospital, Capital Medical University","RECRUITING","Beijing","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":48,"role":30,"phone":31,"phoneExt":24,"email":32},"Xiao, Dr.",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Wang Tianlong","Dr.","100629805","oliceridine-versus-sufentanil-for-postoperative-nausea-in-cerebellopontine-angle-surgery-100629805",false,"NCT07479446","Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery","Comparative Study of Oliceridine Versus Sufentanil for Patient-Controlled Intravenous Analgesia in Improving Postoperative Nausea in Patients Undergoing Cerebellopontine Angle Region Surgery.","Inclusion Criteria:\n\n* Scheduled for elective CPA region surgery with planned PCIA.\n* Age 18-65 years.\n* ASA physical status I-III.\n* Provides written informed consent.\n\nExclusion Criteria:\n\n* Opioid tolerance (taking opioids ≥1 week, equivalent to oral morphine ≥50 mg\u002Fday or oxycodone ≥30 mg\u002Fday).\n* Severe cardiopulmonary, hepatic, renal, vascular, neurological, hematological, gastrointestinal, or endocrine diseases.\n* Postoperative ICU admission with tracheal intubation.\n* BMI ≤18.5 or ≥30 kg\u002Fm².\n* Participation in another clinical trial within 3 months prior to screening.","ALL","18 Years","65 Years",{"count":64,"type":65},174,"ESTIMATED","INTERVENTIONAL",[68],"NA","This single-center, double-blind, randomized controlled trial aims to determine whether oliceridine for patient-controlled intravenous analgesia (PCIA) can significantly reduce the incidence of postoperative nausea, an opioid-related adverse reaction, compared to sufentanil PCIA in patients undergoing cerebellopontine angle (CPA) region surgery. A secondary objective is to compare the postoperative analgesic effects between the two drugs. The study plans to enroll 174 patients (with a calculated sample size of 164 plus 5% for attrition). The primary outcome is the incidence of nausea within 6-48 hours postoperatively. Secondary outcomes include pain scores at rest and during movement within 48 hours, and other exploratory outcomes such as vomiting incidence, time to first flatus\u002Fdefecation, and gastrointestinal function scores.",[71,72,73,74],"PONV","Cerebellopontine Angle Tumor","Microvascular Decompression Surgery","Postoperative Analgesia","2026-05-20",{"date":77,"type":78},"2026-05-22","ACTUAL",{"date":80,"type":78},"2026-03-25",{"date":82,"type":65},"2027-09-30",{"name":5,"class":6},1]